News & Updates

Real-world study: Combining SGLT2i and pioglitazone may ameliorate at-risk MASH in T2D patients

03 Mar 2025 by

Combined use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and pioglitazone may be a potentially useful strategy to ameliorate metabolic dysfunction–associated steatohepatitis (MASH) in patients with type 2 diabetes (T2D), according to a real-world study conducted by researchers from the University of Hong Kong and Queen Mary Hospital (QMH).

Real-world study: Combining SGLT2i and pioglitazone may ameliorate at-risk MASH in T2D patients

03 Mar 2025

Weight loss plays crucial role in diabetes remission

02 Mar 2025

Bodyweight loss appears to have a strong, independent dose-response association with type 2 diabetes (T2D) remission among people with obesity or overweight, according to the results of a meta-analysis.

Weight loss plays crucial role in diabetes remission

02 Mar 2025

Comorbid hypertension, diabetes up CVD, death risks

01 Mar 2025

The dual presence of hypertension and diabetes in an individual puts them at increased risks of cardiovascular disease (CVD) and all-cause mortality beyond those associated with either condition alone, reveals a study.

Comorbid hypertension, diabetes up CVD, death risks

01 Mar 2025

Sotagliflozin: First SGLT inhibitor to show ischaemic benefit

01 Mar 2025

The dual sodium–glucose co-transporter (SGLT) 1/2 inhibitor sotagliflozin appears to reduce the risk of major adverse cardiovascular events (MACE), especially myocardial infarction and stroke—a benefit that has not been previously observed with other drugs of the same class—in patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk, according to the secondary analysis of the SCORED trial.

Sotagliflozin: First SGLT inhibitor to show ischaemic benefit

01 Mar 2025

Do GLP-1 RAs reduce VTE risk in T2D?

28 Feb 2025 by

New data from a study of 656,588 patients with type 2 diabetes (T2D) demonstrate a lower risk of venous thromboembolism (VTE), regardless of obesity status, when treated with glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs).

Do GLP-1 RAs reduce VTE risk in T2D?

28 Feb 2025

Semaglutide linked to modest increase in risk of nonarteritic anterior ischemic optic neuropathy

27 Feb 2025

The use of semaglutide among individuals with type 2 diabetes (T2D) appears to carry a modest increase in the risk nonarteritic anterior ischemic optic neuropathy (NAION), according to a retrospective study.

Semaglutide linked to modest increase in risk of nonarteritic anterior ischemic optic neuropathy

27 Feb 2025

Obesity impacts symptom severity, prednisone dosing in PMR

27 Feb 2025

Obesity appears to have an impact on both symptom severity and the use of prednisone in patients with polymyalgia rheumatica (PMR), suggests a study. This is potentially driven by subjective pain perception rather than increased inflammation.

Obesity impacts symptom severity, prednisone dosing in PMR

27 Feb 2025

Urea beneficial in managing SIADH-induced hyponatremia

26 Feb 2025

Urea appears safe and effective for treating patients with syndrome of inappropriate antidiuretic hormone secretion (SIADH)-related hyponatremia, according to the results of a meta-analysis.

Urea beneficial in managing SIADH-induced hyponatremia

26 Feb 2025

Metabolic health also factors in obesity-related cancer risk in postmenopausal women

24 Feb 2025 by

New research suggests that metabolic health, not just weight, plays a significant role in the development of obesity-related cancers in postmenopausal women.

Metabolic health also factors in obesity-related cancer risk in postmenopausal women

24 Feb 2025

Plant-based meat may lower cholesterol, weight in adults

24 Feb 2025

Replacing meat with plant-based meat alternatives (PBMAs) results in a reduction in total cholesterol (TC), low-density lipoprotein (LDL)-cholesterol, and body weight in adults without cardiovascular diseases, a study has shown.

Plant-based meat may lower cholesterol, weight in adults

24 Feb 2025

News & Updates

Filter by Specialty:

Specialty:

Real-world study: Combining SGLT2i and pioglitazone may ameliorate at-risk MASH in T2D patients

Real-world study: Combining SGLT2i and pioglitazone may ameliorate at-risk MASH in T2D patients

Weight loss plays crucial role in diabetes remission

Weight loss plays crucial role in diabetes remission

Comorbid hypertension, diabetes up CVD, death risks

Comorbid hypertension, diabetes up CVD, death risks

Sotagliflozin: First SGLT inhibitor to show ischaemic benefit

Sotagliflozin: First SGLT inhibitor to show ischaemic benefit

Do GLP-1 RAs reduce VTE risk in T2D?

Do GLP-1 RAs reduce VTE risk in T2D?

Semaglutide linked to modest increase in risk of nonarteritic anterior ischemic optic neuropathy

Semaglutide linked to modest increase in risk of nonarteritic anterior ischemic optic neuropathy

Obesity impacts symptom severity, prednisone dosing in PMR

Obesity impacts symptom severity, prednisone dosing in PMR

Urea beneficial in managing SIADH-induced hyponatremia

Urea beneficial in managing SIADH-induced hyponatremia

Metabolic health also factors in obesity-related cancer risk in postmenopausal women

Metabolic health also factors in obesity-related cancer risk in postmenopausal women

Plant-based meat may lower cholesterol, weight in adults

Plant-based meat may lower cholesterol, weight in adults